HealthMedical Research
mRNA Cancer Vaccine Slashes Melanoma Recurrence by 49%
Moderna and Merck's mRNA vaccine reduced melanoma recurrence risk by 49% over five years, offering new hope for advanced skin cancer patients.
—4 min read
Tag
2 articles
Moderna and Merck's mRNA vaccine reduced melanoma recurrence risk by 49% over five years, offering new hope for advanced skin cancer patients.
A personalized mRNA cancer vaccine combined with Keytruda reduced melanoma recurrence risk by 49% over five years, according to new clinical trial data.